Panacea Life Sciences Holdings annual ebitda margin
2014
2015
2019
2020
2021
2022
2023
Panacea Life Sciences Holdings EBITDA Margin Growth & History (PLSH)
Panacea Life Sciences Holdings's ebitda margin was −160.72% for fiscal 2023.
View full Panacea Life Sciences Holdings company overviewPanacea Life Sciences Holdings annual ebitda margin history
| Fiscal year | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| 2023 | 2023-12-31 | −160.72% | +80.28 pp |
| 2022 | 2022-12-31 | −241.01% | −37.09 pp |
| 2021 | 2021-12-31 | −203.92% | −164.38 pp |
| 2020 | 2020-12-31 | −39.54% | +2789.79 pp |
| 2019 | 2019-12-31 | −2,829.34% | — |
| 2015 | 2015-12-31 | −181,997.65% | −132881.57 pp |
| 2014 | 2014-12-31 | −49,116.08% | — |
Panacea Life Sciences Holdings quarterly ebitda margin
Q2.14
Q3.14
Q4.15
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q1.25
Q2.25
Q3.25
| Fiscal quarter | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| Q3 2025 | 2025-09-30 | −116.50% | — |
| Q2 2025 | 2025-06-30 | 667.00% | — |
| Q1 2025 | 2025-03-31 | 189.01% | +252.79 pp |
| Q1 2024 | 2024-03-31 | −63.78% | +64.25 pp |
| Q4 2023 | 2023-12-31 | −137.88% | +148.70 pp |
| Q3 2023 | 2023-09-30 | −284.61% | −24.77 pp |
| Q2 2023 | 2023-06-30 | −163.20% | +10.35 pp |
| Q1 2023 | 2023-03-31 | −128.03% | +134.35 pp |
| Q4 2022 | 2022-12-31 | −286.58% | −104.16 pp |
| Q3 2022 | 2022-09-30 | −259.84% | −179.09 pp |
| Q2 2022 | 2022-06-30 | −173.55% | +128.98 pp |
| Q1 2022 | 2022-03-31 | −262.38% | — |
| Q4 2021 | 2021-12-31 | −182.42% | −160.79 pp |
| Q3 2021 | 2021-09-30 | −80.75% | +101.89 pp |
| Q2 2021 | 2021-06-30 | −302.52% | −325.17 pp |
| Q4 2020 | 2020-12-31 | −21.63% | +2171.38 pp |
| Q3 2020 | 2020-09-30 | −182.65% | +2729.31 pp |
| Q2 2020 | 2020-06-30 | 22.65% | +1786.52 pp |
| Q1 2020 | 2020-03-31 | −282.37% | +15632.31 pp |
| Q4 2019 | 2019-12-31 | −2,193.02% | — |
| Q3 2019 | 2019-09-30 | −2,911.95% | — |
| Q2 2019 | 2019-06-30 | −1,763.87% | — |
| Q1 2019 | 2019-03-31 | −15,914.68% | — |
| Q4 2015 | 2015-12-31 | −56,284.04% | — |
| Q3 2014 | 2014-09-30 | −34,954.93% | — |
| Q2 2014 | 2014-06-30 | −7,823.94% | — |
Panacea Life Sciences Holdings ebitda margin trends
Between the periods ended 2014-12-31 and 2023-12-31, Panacea Life Sciences Holdings's ebitda margin increased from −49,116.08% to −160.72%, a change of +48955.36 percentage points. The latest reported quarter, Q3 2025, shows −116.50%.
About the metric
What EBITDA margin means
EBITDA margin measures EBITDA as a percentage of revenue. It can help compare operating profitability over time, but it excludes capital intensity, financing costs, taxes, and other items and is generally unsuitable for financial companies.
Calculation and source
How EBITDA margin is calculated
TickerStat calculates EBITDA margin as EBITDA divided by positive reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Panacea Life Sciences Holdings source filings ↗